| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
24,720,000 |
| Market
Cap: |
N/A |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$ - $ |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile SQZ Biotechnologies is a clinical-stage biotechnology company developing cell therapies for patients with cancer, infectious diseases and other serious conditions. Co. uses its proprietary technology, Cell Squeeze, to squeeze cells through a microfluidic chip, temporarily opening the cell membrane and enabling biologic material of interest, or cargo, to diffuse into the cell. Co. is developing three oncology therapeutic candidates, which include: SQZ® Antigen Presenting Cell, SQZ® Enhanced APC and SQZ® Activating Antigen Carrier. Co. is also developing its SQZ® Tolerizing Antigen Carrier platform with the aim to treat autoimmune diseases by inducing antigen-specific immune tolerance.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
14,326 |
| Total Buy Value |
$0 |
$0 |
$0 |
$50,428 |
| Total People Bought |
0 |
0 |
0 |
1 |
| Total Buy Transactions |
0 |
0 |
0 |
1 |
| Total Shares Sold |
0 |
0 |
0 |
1,183 |
| Total Sell Value |
$0 |
$0 |
$0 |
$3,935 |
| Total People Sold |
0 |
0 |
0 |
1 |
| Total Sell Transactions |
0 |
0 |
0 |
1 |
| End Date |
2024-01-28 |
2023-10-27 |
2023-04-28 |
2022-04-28 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Capasso Richard |
See Remarks |
• – – |
2022-08-15 |
4 |
S |
$3.33 |
$3,935 |
D/D |
(1,183) |
0 |
|
- |
|
| Knopf Lawrence J |
General Counsel |
• – – |
2022-06-30 |
4 |
A |
$2.70 |
$4,011 |
D/D |
1,484 |
1,938 |
|
- |
|
| Sharei Armon |
President and CEO |
• • – |
2022-06-30 |
4 |
A |
$2.70 |
$6,585 |
D/D |
2,436 |
287,884 |
|
- |
|
| Capasso Richard |
See Remarks |
• – – |
2022-06-30 |
4 |
A |
$2.70 |
$3,198 |
D/D |
1,183 |
1,183 |
|
- |
|
| Jensen Klavs F. |
Director |
– • – |
2022-05-25 |
4 |
B |
$3.52 |
$50,428 |
D/D |
14,326 |
353,309 |
2.39 |
- |
|
| Sharei Armon |
President and CEO |
• • – |
2022-01-12 |
4 |
OE |
$1.81 |
$23,530 |
D/D |
13,000 |
285,448 |
|
- |
|
| Sharei Armon |
President and CEO |
• • – |
2021-12-31 |
4 |
A |
$7.59 |
$12,798 |
D/D |
1,686 |
272,448 |
|
- |
|
| Knopf Lawrence J |
General Counsel |
• – – |
2021-12-31 |
4 |
A |
$7.59 |
$3,446 |
D/D |
454 |
454 |
|
- |
|
| Schulman Amy W |
Director |
– • • |
2021-12-22 |
4 |
OE |
$2.02 |
$84,823 |
D/D |
24,130 |
214,814 |
|
- |
|
| Sharei Armon |
President and CEO |
• • – |
2021-12-22 |
4 |
OE |
$1.81 |
$19,999 |
D/D |
11,049 |
270,762 |
|
- |
|
| Schulman Amy W |
Director |
– • • |
2021-12-13 |
4 |
B |
$10.88 |
$40,367 |
I/I |
3,700 |
1,850 |
2.25 |
- |
|
| Sharei Armon |
President and CEO |
• • – |
2021-02-27 |
4 |
OE |
$1.81 |
$14,480 |
D/D |
8,000 |
259,713 |
|
- |
|
| Sharei Armon |
President and CEO |
• • – |
2021-01-08 |
4 |
OE |
$1.81 |
$4,525 |
D/D |
2,500 |
251,713 |
|
- |
|
| Temasek Holdings Ltd |
10% Owner |
– – • |
2020-11-03 |
4 |
B |
$16.00 |
$10,000,000 |
I/I |
625,000 |
2,513,924 |
1.5 |
- |
|
| Temasek Holdings Ltd |
10% Owner |
– – • |
2020-11-03 |
4 |
A |
$0.00 |
$0 |
I/I |
1,888,924 |
1,888,924 |
|
- |
|
| American International Group Inc |
10% Owner |
– – • |
2020-11-03 |
4/A |
B |
$16.00 |
$10,000,000 |
I/I |
625,000 |
625,000 |
1.5 |
- |
|
| American International Group Inc |
10% Owner |
– – • |
2020-11-03 |
4/A |
A |
$0.00 |
$0 |
I/I |
1,620,378 |
70,344 |
|
- |
|
| Arny Schulman, As Trustee The Armon R. Sharei Irre |
10% Owner |
– – • |
2020-11-03 |
4 |
A |
$0.00 |
$0 |
D/D |
11,025 |
385,891 |
|
- |
|
| Invus Public Equities Advisors, Llc |
10% Owner |
– – • |
2020-11-03 |
4 |
B |
$16.00 |
$7,440,000 |
D/D |
465,000 |
1,606,308 |
2.45 |
- |
|
| Invus Public Equities Advisors, Llc |
10% Owner |
– – • |
2020-11-03 |
4 |
A |
$0.00 |
$0 |
D/D |
1,141,308 |
1,141,308 |
|
- |
|
| Polaris Partners Vii, L.p. |
10% Owner |
– – • |
2020-11-03 |
4 |
B |
$16.00 |
$4,000,000 |
I/I |
250,000 |
2,549,306 |
1.5 |
- |
|
| Polaris Partners Vii, L.p. |
10% Owner |
– – • |
2020-11-03 |
4 |
A |
$0.00 |
$0 |
I/I |
2,477,646 |
2,315,652 |
|
- |
|
| Jensen Klavs F. |
Director |
– • – |
2020-11-03 |
4 |
A |
$0.00 |
$0 |
D/D |
14,662 |
338,982 |
|
- |
|
| Schulman Amy W |
Director |
– • • |
2020-11-03 |
4 |
B |
$16.00 |
$4,000,000 |
I/I |
250,000 |
2,549,306 |
2.25 |
- |
|
| Schulman Amy W |
Director |
– • • |
2020-11-03 |
4 |
A |
$0.00 |
$0 |
I/I |
2,753,506 |
275,860 |
|
- |
|
34 Records found
|
|
Page 1 of 2 |
|
|
